Enhanced detection of MRD with cfDNA Fragmentomics.

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001010300	The circulating tumor DNA (ctDNA) mutation-based approach shows limited performance in minimal residual disease (MRD) detection, especially for landmark MRD detection at an early-stage cancer after surgery. Here, A total of 87 NSCLC patients, who received curative surgical resections (23 patients relapsed during follow-up), enrolled in this study. A total of 163 plasma samples, collected at 7 days and 6 months postsurgical, were used for high-throughput sequencing.		1

Publications	Citations
Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics. Wang S, Xia Z, You J, Gu X, Meng F, Chen P, Tang W, Bao H, Zhang J, Wu X, Shao Y, Wang J, Zuo X, Xu L, Yin R. Cancer Res Commun 3: 2023 933-942	4